BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Zhang M, Song W, Cai Q, Zhang L, Sun X, Zou L, Zhang H, Wang L, Xue H. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial. Am J Hematol 2022;97:623-9. [PMID: 35170082 DOI: 10.1002/ajh.26499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun Y, Hong JH, Ning Z, Pan D, Fu X, Lu X, Tan J. Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. Front Pharmacol 2022;13:932914. [DOI: 10.3389/fphar.2022.932914] [Reference Citation Analysis]
2 Al-Warhi T, Aldhahrani A, Althobaiti F, Fayad E, Abu Ali OA, Albogami S, Abu Almaaty AH, Khedr AIM, Bukhari SNA, Zaki I. Design, Synthesis and Cytotoxic Activity Evaluation of Newly Synthesized Amides-Based TMP Moiety as Potential Anticancer Agents over HepG2 Cells. Molecules 2022;27:3960. [PMID: 35745081 DOI: 10.3390/molecules27123960] [Cited by in F6Publishing: 1] [Reference Citation Analysis]